Five year follow up on FFR guided PCI for Stable CAD – What Did We Learn From FAME2?

In the final follow up of the FAME 2 study,  published in The New England Journal of Medicine, five year outcomes were reported comparing percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) to medical therapy alone. The hypothesis had suggested FFR guided PCI would be superior to medical therapy as initial treatment in patients with stable coronary artery disease. Continue reading

Recent Trends of TAVR in France

In a recent study published in the Journal of the American College of Cardiology, the implementation of Transcatheter Aortic Valve Replacement (TAVR) was investigated in France.

Continue reading

High Sensitivity Troponin I and Stable Coronary Artery Disease

A recent study published in the Journal of American College of Cardiology found an association between elevated concentrations of high sensitivity troponin I (hsTnI) with increasing prevalence of coronary artery disease (CAD) in stable patients, who were suspected of coronary artery disease and underwent non-emergent coronary computed tomography angiography (CTA).

Continue reading

Andexanet alfa: Rapid reversal of Factor Xa inhibitors

On Monday, March 12th at ACC 2018 in Orlando, Florida, an interim analysis from the ongoing ANNEXA-4 study demonstrated that the first- in-class reversal drug for direct and indirect factor Xa inhibitors, Andexanet alfa, was able to effectively reverse the anti-factor Xa activity and control major bleeding events among patients taking one of four Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban or enoxaparin). Continue reading